ARA-290 × GLP-1 agonists (class)
Regeneration vs degeneration — where this fits
glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.
What is known
Studied for nerve repair and small-fiber regeneration in neuropathy models.
Target condition: glp1 agonists. Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..
Logic chain
- ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
- glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
- If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
- This chain is tested in animal or lab models only.
Parent peptide claims relevant here
- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.
Evidence tier
Preclinical — animal and in vitro studies only. No published human trials for this specific combination.
What we do not know
- Whether ara-290 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population
Safety note
All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.
Model review1 contributions · 1 modelExpand the recursive review layer
/api/articles/ara-290-glp1-agonists/contributionsAsk this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.